PHILADELPHIA — (Nov. 30, 2021) — Immunotherapies have shown striking clinical benefit in the treatment of many cancers, especially when used in combination with chemotherapy. However, some cancers re…
PHILADELPHIA — (Nov. 23, 2021) — The Commonwealth of Pennsylvania has granted The Wistar Institute $4 million to fund COVID-19 research focused on understanding the impact of COVID-19 on certain at-r…
PHILADELPHIA — (Nov. 11, 2021) — A new study by researchers at The Wistar Institute, an international biomedical research leader in cancer, immunology, infectious disease, and vaccine development, sh…
PHILADELPHIA—(October 14, 2021)—The Wistar Institute is proud to announce Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases, National Institutes of Health…
PHILADELPHIA — (Sept. 22, 2021) —The Wistar Institute and Penn Medicine have been awarded a prestigious $11.7 million Specialized Programs of Research Excellence, or SPORE, grant from the National Ca…
PHILADELPHIA — (Sept. 21, 2021) — Mutations in the ARID1A gene are present in more than 50% of ovarian clear cell carcinomas (OCCC), for which effective treatments are lacking. Scientists at The Wist…
PHILADELPHIA — (Sept. 1, 2021) — The Wistar Institute, an international biomedical research leader in cancer, immunology and infectious diseases, welcomes Amelia Escolano, Ph.D., and Nan Zhang, Ph.D…
PHILADELPHIA — (Aug. 31, 2021) — The Wistar Institute announces the appointment of Italo Tempera, Ph.D., as Associate Director for Cancer Research Career Enhancement at the Institute’s Cancer Center…
PHILADELPHIA — (Aug. 25, 2021) — According to a study by The Wistar Institute, the tumor suppressor Parkin, whose levels are reduced in different cancer types, causes acute metabolic and oxidative st…
PHILADELPHIA — (Aug. 17, 2021) — The Wistar Institute announces that the National Institutes of Health (NIH) granted a five-year, $29.15 million Martin Delaney Collaboratories for HIV Cure Research a…
